On December 4, 2025, GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 4) ("GSK") communicated to IDEAYA Biosciences, Inc. (the "Company") its election to terminate the Collaboration, Option and License Agreement, dated June 15, 2020 (as amended, the "Agreement"). Pursuant to the terms of the Agreement, such termination will be effective ninety (90) days following the date of GSK's written notice. During the ninety-day transition period, GSK will transfer the Werner Helicase (IDE275) and Pol Theta (IDE705) clinical programs to the Company in accordance with the applicable provisions of the Agreement. The Company will evaluate its strategic options for these two programs in 2026, and the update does not change its expectation of cash runway into 2030.
Corporate TransactionOperational UpdateSector Analysis
On December 4, 2025 GSK Terminated Collaboration With IDEAYA Biosciences; GSK Will Transfer The Werner Helicase And Pol Theta Clinical Programs To The Co In Accordance With The Applicable Provisions Of The Agreement; IDEAYA Biosciences Will Evaluate Its Strategic Options For These Two Programs In 2026, And The Update Does Not Change Its Expectation Of Cash Runway Into 2030
Benzinga•December 05, 2025 at 9:26 PM•Full Content
View Original →📊 Workflow Status
✓ CompletedCompleted in 1s
clean_raw_article
✓ completed→
clean_markdown_article
✓ completed→
analyze_article
✓ completed→
link_article_to_stories
⊘ skipped→
analyze_sentiment
✓ completedWorkflow #3590 • Benzinga Article Processing
Started: 21:27:01 • Completed: 21:27:03
View Details →Detected Companies & Sentiment
GSK plc
"strategic realignment"
5
Gist
GSK terminated its collaboration with Ideaya Biosciences, transferring two clinical programs to Ideaya, which will assess strategic options in 2026, with no impact on Ideaya’s cash runway forecast through 2030.
LLM Summary
On December 4, 2025, GSK formally terminated its 2020 collaboration agreement with Ideaya Biosciences, triggering a 90-day transition during which GSK will transfer the Werner Helicase (IDE275) and Pol Theta (IDE705) clinical programs. Ideaya will evaluate strategic options for these programs in 2026, and the change does not affect its projected cash runway into 2030.
Full Article Content
Metadata
Author:
Benzinga Newsdesk
Tickers:
GSK, IDYA
Updated At:
December 05, 2025 at 5:26 PM
Benzinga Channels:
Biotech, News, General
Teaser:
On December 4, 2025, GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 4) ("GSK") communicated to IDEAYA Biosciences, Inc. (the "Company") its election to terminate the Collaboration, Option and License Agreement, dated
Benzinga Stocks:
GSK (NYSE), IDYA (NASDAQ)
Benzinga Article ID:
49242742